Kinin B2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas

Molecular Cancer Research

Volumn 6, Issue 12, 2008, Pages 1946-1956

  Zhang, Weiping ^a   Bhola, Neil ^a   Kalyankrishna, Shailaja ^a   Gooding, William ^a   Hunt, Jennifer ^a   Seethala, Raja ^a   Grandis, Jennifer R ^a   Siegfried, Jill M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2; ENDOTHELIAL CELL GROWTH FACTOR; GEFITINIB; ICATIBANT; LYSINE(LEUCINE 8)DEARGININE 9 BRADYKININ; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MIGRATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; SQUAMOUS CELL; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, BRADYKININ B2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 57749108172     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2197     Document Type: Article

References (42)

1. Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004;279:20927-34.
2. Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003;31:1203-8.
3. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002;62:6329-36.
4. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol 2002;167:1458-63.
5. Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000;275:6868-75.
6. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005;27:1329-39.
7. 2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81.
8. Thomas SM, Bhola NE, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9.
9. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63:2037-41.
10. Zhao Y, Xue Y, Liu Y, et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br J Neurosurg 2005;19:322-6.
11. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002;98:29-35.
12. Exton JH. Phospholipase D-structure, regulation and function. Rev Physiol Biochem Pharmacol 2002;144:1-94.
13. Barki-Harrington L, Bookout AL, Wang G, Lamb ME, Leeb-Lundberg LM, Daaka Y. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochem J 2003;371:581-7.
14. Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 2004;201:84-96.
15. Chen BC, Yu CC, Lei HC, et al. Bradykinin B2 receptor mediates NF-κB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells. J Immunol 2004;173:5219-28.
16. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.
17. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11:6261-9.
18. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
19. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4:1448-55.
20. Yu H, Carretero OA, Juncos LA, Garvin JL. Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension 1998;32:287-92.
21. Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F. B-9972 is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430. J Pharmacol Exp Ther 2007;323:534-46.
22. Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile LP. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor. Mol Pharmacol 2007;72:769-79.
23. Simpson PB, Woollacott AJ, Hill RG, Seabrook GR. Functional characterization of bradykinin analogues on recombinant human bradykinin B(1) and B(2) receptors. Eur J Pharmacol 2000;392:1-9.
24. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73.
25. Zhang SP, Codd EE. Characterization of bradykinin receptors in human lung fibroblasts using the binding of 3[H] [Des-Arg10, Leu9]kallidin and 3[H]NPC17731. Life Sci 1998;62:2302-14.
26. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77.
27. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
28. Ikeda Y, Hayashi I, Kamoshita E, et al. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004;64:5178-85.
29. Dlamini Z, Bhoola K. Esophageal cancer in African blacks of Kwazulu Natal, South Africa: an epidemiological brief. Ethn Dis 2005;15:786-9.
30. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
31. 2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822-9.
32. Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 1994;14:5192-201.
33. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM. STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 2003;278:1671-9.
34. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005;44:262-73.
35. Han JW, Sadowski H, Young DA, Macara IG. Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci U S A 1990;87:3373-7.
36. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65:664-70.
37. Naidoo S, Raidoo DM. Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model. Metab Brain Dis 2006;21:253-65.
38. Akbary AM, Wirth KJ, Scholkens BA. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 1996;33:238-42.
39. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-75.
40. Sacks PG, Parnes SM, Gallick GE, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 1988;48:2858-66.
41. Grenman R, Carey TE, McClatchey KD, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 1991;67:2741-7.
42. Stoner GD, Kaighn ME, Reddel RR, et al. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res 1991;51:365-71.